Imunon Inc Cash Flow Conversion Efficiency
Imunon Inc cash flow conversion efficiency. Based on the latest financial reports, Imunon Inc (IMNN) has a cash flow conversion efficiency ratio of -952.715x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.99 Billion) by net assets ($4.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Imunon Inc (1996–2025)
Cash flow conversion efficiency of Imunon Inc from 1996 to 2025. This chart illustrates how Imunon Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View IMNN stock price and chart for real-time trading data and today's change.
Imunon Inc Cash Flow Conversion Ratio Explained
Imunon Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Imunon Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Imunon Inc ranked by their cash flow conversion efficiency. Also see Imunon Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TruCap Finance Limited
NSE:TRU
|
1.175x |
|
Arrive AI Inc.
NASDAQ:ARAI
|
-1.272x |
|
Gaming Factory S.A.
WAR:GIF
|
-0.051x |
|
Aqua Metals Inc
NASDAQ:AQMS
|
-0.276x |
|
Labat Africa Ltd
JSE:LAB
|
0.143x |
|
Schroder Japan Growth Fund
LSE:SJG
|
0.001x |
|
Alchemy Resources Ltd
AU:ALY
|
-0.023x |
|
Goodbye Kansas Group AB (publ)
ST:GBK
|
0.025x |
Annual Cash Flow Conversion Efficiency for Imunon Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Imunon Inc from 1996 to 2025. Review Imunon Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.06 Million | $-13.90 Million | -1.968x | +55.70% |
| 2024-12-31 | $4.24 Million | $-18.85 Million | -4.442x | -212.65% |
| 2023-12-31 | $13.39 Million | $-19.02 Million | -1.421x | -80.42% |
| 2022-12-31 | $29.33 Million | $-23.10 Million | -0.788x | -170.85% |
| 2021-12-31 | $55.80 Million | $-16.22 Million | -0.291x | +65.35% |
| 2020-12-31 | $18.61 Million | $-15.62 Million | -0.839x | +39.69% |
| 2019-12-31 | $14.56 Million | $-20.26 Million | -1.392x | -312.24% |
| 2018-12-31 | $20.86 Million | $-7.04 Million | -0.338x | +45.84% |
| 2017-12-31 | $26.70 Million | $-16.64 Million | -0.623x | +77.19% |
| 2016-12-31 | $6.73 Million | $-18.38 Million | -2.733x | -167.43% |
| 2015-12-31 | $20.39 Million | $-20.83 Million | -1.022x | -57.08% |
| 2014-12-31 | $32.83 Million | $-21.35 Million | -0.651x | -115.28% |
| 2013-12-31 | $31.52 Million | $-9.53 Million | -0.302x | +83.68% |
| 2012-12-31 | $11.96 Million | $-22.14 Million | -1.851x | -113.22% |
| 2011-12-31 | $26.19 Million | $-22.74 Million | -0.868x | -129.72% |
| 2010-12-31 | $-4.58 Million | $-13.37 Million | 2.921x | +3251.52% |
| 2009-12-31 | $10.04 Million | $-930.33K | -0.093x | -180.16% |
| 2008-12-31 | $19.73 Million | $2.28 Million | 0.116x | +136.99% |
| 2007-12-31 | $30.65 Million | $-9.58 Million | -0.313x | -113.84% |
| 2006-12-31 | $-3.20 Million | $-7.23 Million | 2.260x | +195.98% |
| 2005-12-31 | $3.43 Million | $-8.06 Million | -2.354x | -102.16% |
| 2004-12-31 | $11.97 Million | $-13.94 Million | -1.165x | -72.38% |
| 2003-12-31 | $13.45 Million | $-9.09 Million | -0.676x | +88.76% |
| 2002-12-31 | $1.52 Million | $-9.11 Million | -6.008x | -157.70% |
| 2001-12-31 | $2.67 Million | $-6.22 Million | -2.332x | -426.22% |
| 2000-12-31 | $8.73 Million | $-3.87 Million | -0.443x | +80.74% |
| 1999-12-31 | $1.00 Million | $-2.30 Million | -2.300x | -301.53% |
| 1998-12-31 | $-1.85 Million | $-2.11 Million | 1.141x | +143.19% |
| 1997-12-31 | $-2.46 Million | $-1.15 Million | 0.469x | +316.77% |
| 1996-12-31 | $6.76 Million | $-1.46 Million | -0.216x | -- |
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase fo… Read more